ContraVir Pharmaceuticals (CTRV) Trading Down 4.3%

Shares of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) dropped 4.3% during mid-day trading on Monday . The stock traded as low as $0.22 and last traded at $0.22. Approximately 1,617,300 shares were traded during mid-day trading, an increase of 22% from the average daily volume of 1,326,067 shares. The stock had previously closed at $0.23.

CTRV has been the topic of several recent research reports. ValuEngine raised ContraVir Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. Maxim Group set a $4.00 price target on ContraVir Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, February 12th.

A hedge fund recently bought a new stake in ContraVir Pharmaceuticals stock. Anson Funds Management LP bought a new stake in ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 1,237,957 shares of the biopharmaceutical company’s stock, valued at approximately $446,000. ContraVir Pharmaceuticals comprises 0.3% of Anson Funds Management LP’s portfolio, making the stock its 26th biggest position. Anson Funds Management LP owned approximately 1.57% of ContraVir Pharmaceuticals as of its most recent SEC filing. Institutional investors own 8.55% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “ContraVir Pharmaceuticals (CTRV) Trading Down 4.3%” was first published by Markets Daily and is owned by of Markets Daily. If you are accessing this news story on another site, it was copied illegally and reposted in violation of US & international copyright law. The original version of this news story can be accessed at

About ContraVir Pharmaceuticals

ContraVir Pharmaceuticals, Inc is focused on curing hepatitis B through the combination of direct and indirect acting antiviral compounds. Its two assets tenofovir exalidex, or TXL, and CRV431 have complementary mechanisms of action and have shown potential synergy against hepatitis B virus (HBV). TXL is designed to deliver high intrahepatic concentrations of TFV while minimizing off target effects caused by high levels of circulating TFV, and has completed a Phase IIa trial.

Receive News & Ratings for ContraVir Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply